Rating Change
HC Wainwright & Co. reiterated its Buy rating on Journey Medical Corporation (NASDAQ:DERM) on October 26, 2026.
reiterateNASDAQ:DERM
HC Wainwright & Co. Reiterates Buy Rating on Journey Medical Corporation (DERM)
HC Wainwright & Co. reiterated its Buy rating on Journey Medical Corporation (NASDAQ:DERM) on October 26, 2026.
At publication ·
What changed
Journey Medical Corporation (NASDAQ:DERM) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $4.97
- Market capitalization
- $178.6M
At a glance
Key takeaways
- Journey Medical Corporation (DERM) trades at $4.97 with a $178.6M market cap and has declined 31.5% over the past 52 weeks.
Market Context
Journey Medical Corporation operates in the Healthcare sector. The stock currently trades at $4.97 with a market capitalization of $178.6M. The stock has declined 31.5% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Journey Medical Corporation.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Journey Medical Corporation
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 26, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 13, 2026 | B. Riley Securities | Buy | N/A |
| Mar 26, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 25, 2025 | HC Wainwright & Co. | Buy | N/A |
| Aug 13, 2025 | Lake Street | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View DERM Stock Page
Frequently Asked Questions
What does the Buy rating mean for DERM?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Journey Medical Corporation (NASDAQ:DERM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the DERM forecast page.